Related Experiment Video
Updated: Feb 27, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.4K
[Gliptin-gliflozin combination for treating type 2 diabetes]
André J Scheen1,2, Nicolas Paquot1
1Service de diabétologie, nutrition et maladies métaboliques, Département de médecine, CHU Liège, 4000 Liège, Belgique.
Revue Medicale Suisse
|July 4, 2017
Summary
Combining dipeptidyl peptidase-4 inhibitors (DPP-4i) and sodium-glucose cotransporter type 2 inhibitors (SGT2i) offers a potent and safe dual therapy for type 2 diabetes (T2D) management. This approach is more effective than monotherapy and available in fixed-dose combinations.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Type 2 diabetes (T2D) is a complex metabolic disorder characterized by hyperglycemia.
- Effective T2D management often necessitates combination pharmacotherapy due to multiple underlying defects.
- Current treatment guidelines recommend intensifying therapy to achieve glycemic control.
Purpose of the Study:
- To evaluate the efficacy and safety of combining dipeptidyl peptidase-4 inhibitors (DPP-4i) with sodium-glucose cotransporter type 2 inhibitors (SGT2i) for T2D.
- To compare dual therapy with monotherapy in patients with T2D.
- To highlight the potential of fixed-dose combinations (FDCs) in T2D management.
Main Methods:
- Review of clinical studies investigating dual therapy with DPP-4i and SGT2i.
- Analysis of data comparing combination therapy (initial or stepwise) versus monotherapy.
- Assessment of safety profiles, including hypoglycemia incidence.
Main Results:
- Dual therapy with DPP-4i and SGT2i demonstrates superior glucose-lowering effects compared to monotherapy.
- This combination is effective in patients on diet/exercise or already treated with metformin.
- The combination therapy is safe and does not increase the risk of hypoglycemia.
Conclusions:
- Combining DPP-4i and SGT2i represents an attractive and effective strategy for T2D management.
- Fixed-dose combinations of these agents are available and facilitate treatment adherence.
- Further development of dual therapies is ongoing, offering expanded options for T2D patients.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
786
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
786
01:06Oral Hypoglycemic Agents: Glinides
758
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
758
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
739
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
739
01:24Glucagon-like Receptor Agonists
1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
01:22Diabetes Mellitus: Type 2 and Gestational
5.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.2K
01:15Diabetes: Management and Pharmacotherapy
1.2K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K